Chemotherapy combined with Endostar as salvage treatment for EGFR‐tyrosine kinase inhibitor primary resistance in an advanced non‐small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chemotherapy combined with Endostar as salvage treatment for EGFR‐tyrosine kinase inhibitor primary resistance in an advanced non‐small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report

Published:2019-02-18 Issue:4 Volume:10 Page:1023-1028
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Qiu Dong¹²^ORCID,Zhang Yu²,Xue Ying‐bo²,Shen Qi²,Li Hang²,Huang Ping³,Hu Jian‐jun³,Wang Yong‐sheng¹^ORCID

Affiliation:

1. Department of Thoracic Oncology, State Key Laboratory of Biotherapy and Cancer Center, West China HospitalSichuan University and Collaborative Innovation Center of Biotherapy Chengdu China

2. Department of OncologyGuizhou People's Hospital Guiyang China

3. Department of PathologyGuizhou People's Hospital Guiyang China

Funder

Guizhou High-level Innovative Talents Foundation

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13003

Reference18 articles.

1. Cancer statistics, 2017

2. Cancer statistics in China, 2015

3. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

4. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

5. Recent advances in targeting ROS1 in lung cancer;Lin JJ;J Clin Oncol,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report;OncoTargets and Therapy;2021-08

2. Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients;Journal of Thoracic Disease;2019-12

3. Cisplatin/endostatin/pemetrexed;Reactions Weekly;2019-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3